November 2, 2018




Eric F. Fess, Esq.
Chapman and Cutler LLP
111 West Monroe Street
Chicago, Illinois 60603


Re:    Guggenheim Defined Portfolios, Series 1833
       File Nos. 333-227765 and 811-03763

Dear Mr. Fess:

       On October 10, 2018, you filed a registration statement on Form S-6 for
Guggenheim
Defined Portfolios, Series 1833 (the "Fund"), consisting of a unit investment
trust, Quality
Quantamental Portfolio, Series 1 (the "trust"). We have reviewed the
registration statement, and
have provided our comments below. For convenience, we generally organized our
comments
using headings and defined terms from the registration statement. Where a
comment is made in
one location, it is applicable to all similar disclosure appearing elsewhere in
the registration
statement.

PROSPECTUS

Investment Summary -- Principal Investment Strategy

1.      The second sentence of this section states that "Quantamental investing
is the
combination of quantitative and fundamental investment techniques." Please
explain in this
section the differences between quantitative investment techniques and
fundamental investment
techniques. Please also provide a clear explanation of how these two investment
techniques
select securities.
 Eric F. Fess, Esq.
November 2, 2018
Page 2


2.       This section states that the trust consists of "U.S.-listed common
stocks." Please clarify
in this section whether the common stocks held in the trust may include those
of foreign and/or
emerging market issuers. If so, please provide corresponding risk disclosures.

3.      This section also states that the sponsor will select the trust
portfolio's constituents "with
the assistance of Wells Fargo Securities Equity Research Team." Please explain
to us why Wells
Fargo Securities Equity Research Team should not be considered an investment
adviser to the
trust pursuant to Section 2(a)(20) of the Investment Company Act of 1940 (the
"Investment
Company Act"), and therefore subject to the requirements of Section 15 of the
Investment
Company Act. In your explanation, please give additional details regarding the
role that Wells
Fargo plays in selecting portfolio constituents, as well as how Wells Fargo is
compensated for its
assistance (e.g., a flat fee or a percentage of trust assets).

Investment Summary -- Security Selection

4.      The second bullet of this section states that the Fund may invest in
securities with market
capitalizations as low as $3 billion. Please include the risks of small
capitalization companies in
the discussions of the trust's principal risks.

Investment Summary -- Principal Risks

5.    Please provide a risk stating that the stock selection criteria used in
the trust's
Quantamental investment strategy may not produce the desired investment
results.

Investment Summary -- Fees and Expenses

6.      Footnote (3) to the fee table states that the creation and development
fee "is $0.050 per
unit and is paid to the sponsor at the close of the initial offering period."
Please also disclose in
this footnote whether shareholders who invest after the close of the initial
offering period will be
required to pay the creation and development fee.

GENERAL COMMENTS

7.     Please advise us whether you have submitted or expect to submit any
exemptive
applications or no-action requests in connection with your registration
statement.

8.     We note that portions of the filing are incomplete. We may have
additional comments on
such portions when you complete them in pre-effective amendments, on
disclosures made in
response to this letter, on information you supply to us, or on exhibits added
in any pre-effective
amendments.

9.     Responses to this letter should be in the form of a pre-effective
amendment filed pursuant
to Rule 472 under the Securities Act. Where no change will be made in the
filing in response to
a comment, please indicate this fact in a letter to us and briefly state the
basis for your position.
 Eric F. Fess, Esq.
November 2, 2018
Page 3


                                        *******

        In closing, we remind you that the trust and its sponsor are
responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

        Should you have any questions prior to filing a pre-effective
amendment, please feel free
to contact me at 202-551-6959.



Sincerely,

                                                                         /s/
Edward P. Bartz


Edward P. Bartz

Senior Counsel




cc:    Michael J. Spratt
       Michael J. Shaffer